Counting Points Was So 90’s. Weight Watchers (WW) Soars Over 40% On Compounded GLP-1 Offering
WeightWatchers (WW) announced it will be adding compounded semaglutide to is offering. This will enhance the company’s holistic weight management program and provide its members to access to behavioral and clinical solutions with support from board-certified clinicians, registered dietitians, and the global WeightWatchers community.
Approximately 45% of WeightWatchers Clinic members eligible for and prescribed a GLP-1 by their clinician have been denied coverage by their insurance and shortages of GLP-1 medications have been increasing for over two years as name-brand medications are out of stock at many local pharmacies.
“Given the ongoing shortages of branded medications such as Ozempic and Wegovy, WeightWatchers is committed to ensuring our members still have access to effective alternatives and the support they need to achieve the health outcomes they deserve,” stated Tara Comonte, Interim CEO of WeightWatchers.
“We know that compounded semaglutide can be an important option for those seeking weight loss support, given its greater availability and affordability,” said Dr. Jamil Alkhaddo, Medical Director of WeightWatchers. “In fact, over 50% of current WeightWatchers members have expressed consideration of a compounded GLP-1 for their journey.3 That’s why, after months of thorough research, and careful evaluation of multiple facilities, we partnered with a trusted, FDA-registered 503B facility that meets our high standards for quality and patient care — so our eligible members can feel confident in this new option as a trusted part of their weight loss plan.”
Weight Watchers continues to lead the PRISM Weight Loss Index as the stock trades up over 40% today.
